| Pair Name | Beta-Cryptoxanthin, Oxaliplatin | ||
| Phytochemical Name | Beta-Cryptoxanthin (PubChem CID: 5281235 ) | ||
| Anticancer drug Name | Oxaliplatin (PubChem CID: 9887053 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Drug Name | Oxaliplatin |
| Adverse Reactions | Nausea, vomiting, diarrhoea, loss of appetite. This was inferred cold nature anticancer drug. |
| Recommendations | Hot: Datura metel; Citrus reticulata |
| Reference | Traditional Chinese medicine characteristics of chemotherapy regimens in advanced gastrointestinal malignant tumours[J]. Global Traditional Chinese Medicine,2023,16(8):1596-1599. DOI:10.3969/j.issn.1674-1749.2023.08.019. ref_link |
| Pair Name | Beta-Cryptoxanthin, Oxaliplatin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | TP73 | hsa7161 |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW1417 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_1717 | |
| In Vivo Model | 1×10⁶ HCT116 cells and 1×10⁶ and 107 SW480 cells suspended in 20% matrigel were subcutaneously injected to nude mice (Hsd:Athymic Nude-Foxn1nu, female, 6 weeks old). | |||
| Result | We propose a putative novel therapeutic strategy for the treatment of colon cancer based on the combination of β-cryptoxanthin and oxaliplatin. The combined regimen produced more benefit than either individual modality without increasing side effects. In addition, the concentration-limiting toxicity of oxaliplatin is reduced in the presence of the carotenoid. | |||
| No. | Title | Href |
|---|---|---|
| 1 | β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer. Clin Cancer Res. 2015 Oct 1;21(19):4398-409. doi: 10.1158/1078-0432.CCR-14-2027. | Click |
